{"id":"https://openalex.org/W2010562953","doi":"https://doi.org/10.1200/edbook_am.2013.33.294","title":"Monoclonal Antibody-Based Therapies in the Treatment of Acute Lymphoblastic Leukemia","display_name":"Monoclonal Antibody-Based Therapies in the Treatment of Acute Lymphoblastic Leukemia","publication_year":2013,"publication_date":"2013-01-01","ids":{"openalex":"https://openalex.org/W2010562953","doi":"https://doi.org/10.1200/edbook_am.2013.33.294","mag":"2010562953","pmid":"https://pubmed.ncbi.nlm.nih.gov/23714527"},"language":"en","primary_location":{"id":"doi:10.1200/edbook_am.2013.33.294","doi":"https://doi.org/10.1200/edbook_am.2013.33.294","is_oa":false,"landing_page_url":"https://doi.org/10.1200/edbook_am.2013.33.294","pdf_url":null,"source":{"id":"https://openalex.org/S4210215109","display_name":"American Society of Clinical Oncology Educational Book","issn_l":"1548-8748","issn":["1548-8748","1548-8756","1930-7020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","ki-jl-1","medline","poland-40","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320068","host_organization_name":"American Society of Clinical Oncology","host_organization_lineage":["https://openalex.org/P4310320068"],"host_organization_lineage_names":["American Society of Clinical Oncology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Society of Clinical Oncology Educational Book","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085360755","display_name":"Mark Robert Litzow","orcid":"https://orcid.org/0000-0002-9816-6302","observed_orcids":["https://orcid.org/0000-0002-9816-6302"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Mark R. Litzow","raw_affiliation_strings":["From the Division of Hematology, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Division of Hematology, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5085360755"],"corresponding_institution_ids":["https://openalex.org/I1330342723"],"apc_list":null,"apc_paid":null,"fwci":3.3789,"has_fulltext":false,"cited_by_count":15,"citation_normalized_percentile":{"value":0.91611231,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"33","issue":"33","first_page":"294","last_page":"299"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-lymphoblastic-leukemia","display_name":"acute lymphoblastic leukemia","score":0.9779999852180481},{"id":"https://openalex.org/keywords/monoclonal-antibody-therapy","display_name":"monoclonal antibody therapy","score":0.902999997138977},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9610000252723694},{"id":"https://openalex.org/keywords/inotuzumab-ozogamicin","display_name":"inotuzumab ozogamicin","score":0.9980000257492065},{"id":"https://openalex.org/keywords/anti-cd22-antibody","display_name":"anti-CD22 antibody","score":0.8429999947547913},{"id":"https://openalex.org/keywords/blinatumomab","display_name":"blinatumomab","score":0.871999979019165},{"id":"https://openalex.org/keywords/bispecific-t-cell-engagers","display_name":"bispecific T-cell engagers","score":0.847000002861023},{"id":"https://openalex.org/keywords/chimeric-antigen-receptor-t-cells","display_name":"chimeric antigen receptor T cells","score":0.8370000123977661},{"id":"https://openalex.org/keywords/relapsed-refractory-leukemia","display_name":"relapsed/refractory leukemia","score":0.765999972820282},{"id":"https://openalex.org/keywords/older-adults","display_name":"older adults","score":0.7400000095367432},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.828000009059906},{"id":"https://openalex.org/keywords/combination-chemotherapy-toxicity","display_name":"combination chemotherapy toxicity","score":0.4399999976158142}],"concepts":[{"id":"https://openalex.org/C2778020697","wikidata":"https://www.wikidata.org/wiki/Q410189","display_name":"Blinatumomab","level":4,"score":0.8737465143203735},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.714015007019043},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7119044661521912},{"id":"https://openalex.org/C2778245361","wikidata":"https://www.wikidata.org/wiki/Q409744","display_name":"Calicheamicin","level":3,"score":0.6358323097229004},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.6266778707504272},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.5700865983963013},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5321525931358337},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.5026533603668213},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4928853511810303},{"id":"https://openalex.org/C115085202","wikidata":"https://www.wikidata.org/wiki/Q425665","display_name":"Immunotoxin","level":4,"score":0.45454853773117065},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.449005663394928},{"id":"https://openalex.org/C2778623314","wikidata":"https://www.wikidata.org/wiki/Q412685","display_name":"Gemtuzumab ozogamicin","level":5,"score":0.4412006139755249},{"id":"https://openalex.org/C2777843201","wikidata":"https://www.wikidata.org/wiki/Q17163357","display_name":"Monoclonal antibody therapy","level":4,"score":0.43579739332199097},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4232952892780304},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.41514822840690613},{"id":"https://openalex.org/C2779015954","wikidata":"https://www.wikidata.org/wiki/Q420164","display_name":"Alemtuzumab","level":3,"score":0.4124349355697632},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3954927921295166},{"id":"https://openalex.org/C2778957590","wikidata":"https://www.wikidata.org/wiki/Q798033","display_name":"CD19","level":3,"score":0.33840373158454895},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.205835223197937},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.1845855712890625},{"id":"https://openalex.org/C176290653","wikidata":"https://www.wikidata.org/wiki/Q21114013","display_name":"CD33","level":4,"score":0.17045068740844727},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1302815079689026},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C10205521","wikidata":"https://www.wikidata.org/wiki/Q4035578","display_name":"CD34","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000080045","descriptor_name":"Inotuzumab Ozogamicin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000922","descriptor_name":"Immunotoxins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000922","descriptor_name":"Immunotoxins","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018033","descriptor_name":"Antibodies, Bispecific","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D051918","descriptor_name":"Sialic Acid Binding Ig-like Lectin 2","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1200/edbook_am.2013.33.294","doi":"https://doi.org/10.1200/edbook_am.2013.33.294","is_oa":false,"landing_page_url":"https://doi.org/10.1200/edbook_am.2013.33.294","pdf_url":null,"source":{"id":"https://openalex.org/S4210215109","display_name":"American Society of Clinical Oncology Educational Book","issn_l":"1548-8748","issn":["1548-8748","1548-8756","1930-7020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","ki-jl-1","medline","poland-40","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320068","host_organization_name":"American Society of Clinical Oncology","host_organization_lineage":["https://openalex.org/P4310320068"],"host_organization_lineage_names":["American Society of Clinical Oncology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Society of Clinical Oncology Educational Book","raw_type":"journal-article"},{"id":"doi:10.14694/edbook_am.2013.33.294","doi":"https://doi.org/10.14694/edbook_am.2013.33.294","is_oa":false,"landing_page_url":"https://doi.org/10.14694/edbook_am.2013.33.294","pdf_url":null,"source":{"id":"https://openalex.org/S4210215109","display_name":"American Society of Clinical Oncology Educational Book","issn_l":"1548-8748","issn":["1548-8748","1548-8756","1930-7020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","ki-jl-1","medline","poland-40","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320068","host_organization_name":"American Society of Clinical Oncology","host_organization_lineage":["https://openalex.org/P4310320068"],"host_organization_lineage_names":["American Society of Clinical Oncology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Society of Clinical Oncology Educational Book","raw_type":"journal-article"},{"id":"pmid:23714527","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23714527","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W1963522404","https://openalex.org/W1999624685","https://openalex.org/W2005395372","https://openalex.org/W2010729137","https://openalex.org/W2026177698","https://openalex.org/W2031452426","https://openalex.org/W2038414910","https://openalex.org/W2066064966","https://openalex.org/W2076890670","https://openalex.org/W2082189475","https://openalex.org/W2091264926","https://openalex.org/W2106275447","https://openalex.org/W2120104555","https://openalex.org/W2122921932","https://openalex.org/W2123755151","https://openalex.org/W2126855868","https://openalex.org/W2127742735","https://openalex.org/W2128272164","https://openalex.org/W2130011407","https://openalex.org/W2164006259","https://openalex.org/W4255309549"],"related_works":["https://openalex.org/W2087640820","https://openalex.org/W2946805300","https://openalex.org/W2055401871","https://openalex.org/W2908115938","https://openalex.org/W1600925615","https://openalex.org/W2166899683","https://openalex.org/W2127516396","https://openalex.org/W2087506557","https://openalex.org/W2075275816","https://openalex.org/W2026698098"],"abstract_inverted_index":{"Recent":[0],"studies":[1],"have":[2,154,173],"suggested":[3],"that":[4,73,107],"pediatric-intensive":[5],"chemotherapy":[6,48],"regimens":[7],"can":[8],"improve":[9],"outcomes":[10],"in":[11,79,94,121,138,158,167,180,192,197],"adults":[12],"with":[13,128],"acute":[14],"lymphoblastic":[15],"leukemia":[16],"(ALL)":[17],"up":[18],"to":[19,46,58,71,88,112,124,176],"the":[20,33,140,146,174,198],"age":[21],"of":[22,35,44,97,170,184,186,195,200],"45.":[23],"Above":[24],"this":[25],"age,":[26],"toxicities":[27],"increase.":[28],"Monoclonal":[29],"antibody-based":[30,55,189],"therapies":[31,56,190],"bring":[32],"promise":[34],"increased":[36],"response":[37,178],"rates":[38,179],"without":[39],"excessive":[40],"toxicity.":[41],"The":[42],"addition":[43],"rituximab":[45],"combination":[47],"has":[49,74,134],"shown":[50,155],"encouraging":[51,136],"results.":[52],"Newer":[53],"monoclonal":[54,85,188],"linked":[57,70,87],"cytotoxic":[59],"agents":[60,172],"show":[61],"promise.":[62],"These":[63],"include":[64],"inotuzumab":[65],"ozogamicin,":[66],"an":[67],"anti-CD22":[68],"antibody":[69,106],"calicheamicin":[72],"produced":[75],"significant":[76],"single-agent":[77],"responses":[78,157],"relapsed":[80],"and":[81,114,116,145,163],"refractory":[82],"ALL.":[83,168,203],"Other":[84],"antibodies":[86,111],"plant":[89],"or":[90],"bacterial":[91],"toxins":[92],"are":[93,164,191],"earlier":[95],"stages":[96,194],"development.":[98],"Blinatumomab":[99],"is":[100],"a":[101,118,125],"novel":[102],"bispecific":[103],"T-cell":[104],"engaging":[105],"combines":[108],"single":[109],"chain":[110],"CD19":[113],"CD3":[115],"brings":[117],"T":[119],"cell":[120],"close":[122],"proximity":[123],"leukemic":[126],"lymphoblast":[127],"resulting":[129],"redirected":[130],"lysis.":[131],"This":[132],"agent":[133],"demonstrated":[135],"results":[137],"both":[139],"minimal":[141],"residual":[142],"disease":[143],"setting":[144],"relapsed/refractory":[147],"setting.":[148],"Autologous":[149],"chimeric":[150],"antigen":[151],"receptor":[152],"cells":[153],"promising":[156],"indolent":[159],"B-cell":[160],"lymphoid":[161],"malignancies":[162],"being":[165],"tested":[166],"Many":[169],"these":[171,187],"potential":[175],"increase":[177],"older":[181],"adults.":[182],"Trials":[183],"many":[185],"various":[193],"development":[196],"treatment":[199],"newly":[201],"diagnosed":[202]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}